about
Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Recent therapeutic advances in chronic lymphocytic leukemia.T-PLL: another check on the venetoclax list?In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer.Critical molecular pathways in CLL therapy.Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
P2860
Q38637652-EAEA582F-BE47-4FEE-84F8-C8697412249EQ38818283-62580036-245F-4788-A6D7-FE13AD4A93B0Q46318389-AD8F8A27-5CD1-467B-A5E9-7CE37F0095A4Q47235165-E654188A-9156-45EF-9E12-5A5C71F24A68Q53159453-2D648026-F043-4ED5-9F7C-C2C7B4077B55Q55447785-E79C7443-A162-4A77-BAB8-F46D8B2D6828Q57162415-92AC4EF6-13F1-4F8B-86EB-FB97520F4439
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Pathways and mechanisms of venetoclax resistance.
@en
Pathways and mechanisms of venetoclax resistance.
@nl
type
label
Pathways and mechanisms of venetoclax resistance.
@en
Pathways and mechanisms of venetoclax resistance.
@nl
prefLabel
Pathways and mechanisms of venetoclax resistance.
@en
Pathways and mechanisms of venetoclax resistance.
@nl
P2860
P1433
P1476
Pathways and mechanisms of venetoclax resistance.
@en
P2093
Prithviraj Bose
Varsha Gandhi
P2860
P356
10.1080/10428194.2017.1283032
P577
2017-01-31T00:00:00Z